Option chain shows key data for Revelation Biosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Revelation Biosciences.

Revelation Biosciences (NASDAQ:REVBW) Stock, Option Chain

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Revelation Biosciences Inc

Biotech

News

Health Care

General

TRAW

Traws Pharma Announced Completion Of Phase 1 Clinical Studies Of Its Investigational One-dose Influenza Therapy, Tivoxavir Marboxil (Tivoxavir), For The Treatment Or Prevention Of H5N1 Bird Flu.

PLUR

Pluri shares are trading higher after the company announced a private placement and the acquisition of a 71% stake in Kokomodo.

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $16 price target.

Price Target

Reiteration

Analyst Ratings

ESPR

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

Pluri Announces $6.5M Private Placement With Investor Alejandro Weinstein; Co. Will Purchase ~71% Of Kokomodo's Shares

WIIM

Shares of airline stocks are trading lower following weak guidance from American Airlines.

BEAM

Beam Therapeutics To Encore Data From BEACON Phase 1/2 Clinical Trial Of BEAM-101 In Sickle Cell Disease At Tandem Meetings Of ASTCT And CIBMTR

Raymond James analyst Steve Moss upgrades First Community (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCCO#NASDAQ">FCCO</a>) from Outperform to Strong Buy and raises the price target from $27 to $30.

Upgrades

FCCO

Raymond James Upgrades First Community to Strong Buy, Raises Price Target to $30

On Wednesday, January 22, U.S. markets closed higher, with the S&amp;P 500 reaching a record high as Netflix gained significantly after reporting record subscribers and announcing price increases. Technology stocks, driven by AI leaders like Nvidia and Microsoft, led gains. Despite unclear funding details, investors were optimistic about President Trump&#8217;s private-sector AI investment plan.
In economic data, U.S. mortgage applications increased slightly from the prior week during the week ending January 17.
Most S&amp;P 500 sectors declined, but information technology and communication services stocks closed higher, defying the overall trend.
The Dow Jones Industrial Average was up 0.30% and closed at 44,156.73, the S&amp;P 500 closed higher by 0.61% at 6,086.37, and the Nasdaq Composite rose 1.28% to finish at 20,009.34.
Aisa Markets Today
<ul>
<li>On Thursday, Japan&#8217;s Nikkei 225 closed higher by 0.98% at 40,003.50, led by gains in the Precision Instruments, Communication, and Non-Metal Minerals sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 declined 0.61%, ending the session at 8,378.70, led by losses in the Metals &amp; Mining, Consumer Discretionary, and Materials sectors.</li>
<li>India&#8217;s Nifty 50 closed higher by 0.25% at 23,213.75, and the Nifty 500 rose 0.65%, closing at 21,536.10, led by gains in the Consumer Durables, Real Estate, and Technology sectors.</li>
<li>China&#8217;s Shanghai Composite gained 0.51% and closed at 3,230.16, and the Shenzhen CSI 300 rose 0.18%, finishing the day at 3,803.74.</li>
<li>Hong Kong&#8217;s Hang Seng closed the session lower by 0.40% at 19,700.56.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 was down 0.06%.</li>
<li>Germany&#8217;s DAX rose 0.24%.</li>
<li>France&#8217;s CAC was up 0.23%.</li>
<li>U.K.&#8217;s FTSE index 100 traded lower by 0.06%.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 0.19% at $75.31/bbl, and Brent was down 0.14% at $78.91/bbl.</li>
<li>Oil prices remained steady, weighed down by uncertainty over U.S. tariffs, energy policies, and rising crude inventories.</li>
<li>Natural Gas declined 0.45% to $3.942.</li>
<li>Gold was trading lower by 0.54% at $2,756.10, Silver was down 1.00% to $31.105, and Copper fell 0.42% to $4.2380.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures were up 0.05%, S&amp;P 500 futures fell 0.17% and Nasdaq 100 futures declined 0.49%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. Dollar Index declined 0.07% to 108.18, USD/JPY fell 0.11% to 156.32, and USD/AUD gained 0.07% to 1.5951.</li>
<li>The dollar traded within tight ranges on Thursday, lacking direction amid uncertainty over President Trump&#8217;s U.S. tariff announcements.</li>
</ul>
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Equities

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Mixed; Dollar Index Ticks Lower - Global Markets Today While US Slept

"Under the terms of the MOU, IonQ plans to provide quantum computing cloud services, support the planning and execution of joint quantum initiatives, and contribute to the workforce and economic development of South Korea. In turn, the Busan Metropolitan Government will help create an environment conducive to the growth of the quantum technology sector."

IONQ

IonQ Signs MoU With The Busan Metropolitan Government in South Korea; Co. Plans To Provide Quantum Computing Cloud Services And Support Quantum Initiatives

The investment marks an important milestone in Visa's commitment to advancing financial inclusion and shaping the future of digital payments while fostering SME growth across Africa.

Nigeria's Moniepoint Secures Investment From Visa; No Terms Disclosed

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) with a Buy and raises the price target from $4 to $6.

PGEN

HC Wainwright & Co. Reiterates Buy on Precigen, Raises Price Target to $6

Earnings

CLST

Catalyst Bancorp Q4 2024 GAAP EPS $0.16 Up From $0.08 YoY, Sales $2.81M Up From $2.63M YoY

Raymond James analyst Andrew Marok downgrades Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) from Outperform to Market Perform.

Downgrades

Raymond James Downgrades Electronic Arts to Market Perform

VEEV

Veeva, Zifo Announce Product Partnership To Help Biopharmas Modernize Quality Control Operations

West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTBA#NASDAQ">WTBA</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.40 by 5 percent. This is a 55.56 percent increase over earnings of $0.27 per share from the same period last year.

Earnings Beats

WTBA

West Bancorp Q4 2024 GAAP EPS $0.42 Beats $0.40 Estimate

Raymond James analyst Daniel Magder initiates coverage on Electrovaya (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVA#NASDAQ">ELVA</a>) with a Strong Buy rating and announces Price Target of $4.5.

Initiation

ELVA

Raymond James Initiates Coverage On Electrovaya with Strong Buy Rating, Announces Price Target of $4.5

Rockwell Automation Expands Advanced Technology Team By Opening New Research Lab In Prague, Czech Republic

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) with a Buy and maintains $50 price target.

GMAB

HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target

IDXX

IDEXX Reports Launch Of IDEXX Cancer Dx, A Diagnostic Panel With Early Detection Of Lymphoma In Dogs

Cannabis

Markets

Aurora Cannabis Has Launched Its First German-cultivated Medical Cannabis Product, Under The Brand IndiMed, Manufactured At Aurora's Facility In Leuna, Germany

Comments

Revelation Biosciences

Revelation Biosciences (REVBW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga